NDA Partners Founder and Chairman Carl Peck, MD to Receive 2014 Nathaniel T. Kwit Memorial Distinguished Service Award - KWES NewsWest 9 / Midland, Odessa, Big Spring, TX: newswest9.com |

NDA Partners Founder and Chairman Carl Peck, MD to Receive 2014 Nathaniel T. Kwit Memorial Distinguished Service Award

Posted:

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

NDA Partners founder and Chairman Carl Peck, MD will receive the 2014 Nathaniel T. Kwit Memorial Distinguished Service Award on September 14, 2014 in a ceremony during the annual meeting of the American College of Clinical Pharmacologys (ACCP) in Atlanta, GA.

Rochelle, VA (PRWEB) July 16, 2014

NDA Partners LLC learned today that company founder and Chairman Carl Peck, MD will receive the 2014 Nathaniel T. Kwit Memorial Distinguished Service Award on September 14, 2014 in a ceremony during the annual meeting of the American College of Clinical Pharmacologys (ACCP) in Atlanta, GA. The award is given in memory of the late Nathaniel T. Kwit, MD, FCP, a founding Fellow of the College, who served as a Regent for 5 years and as Treasurer for 20 years. The primary intent of this award is to recognize accomplishments of a general nature which benefit the field of clinical pharmacology. These may be in the area of teaching, administration, service with ACCP or long-term and wide-ranging scientific studies having practical importance and other service-related functions. In presenting the award to Dr. Peck, the College is acknowledging his contributions to the pharmaceutical drug development field, service to the College, and overall contribution to the field of clinical pharmacology.

This award marks another milestone in Dr. Pecks distinguished career as a clinical pharmacologist, regulatory scientist, and prominent contributor to the drug development field, said Earle Martin, Chief Executive Officer of NDA Partners. We extend our congratulations and are grateful for the leadership he brings to the company and the industry.

In conjunction with the receipt of this award, Dr. Peck will give a brief presentation entitled Clinical Pharmacology is the Core Science of Drug Development and Regulation.

Dr. Peck is a Founder, Partner and current Chairman of NDA Partners. He was the founding director of the Center for Drug Development Science at Georgetown University Medical Center, where he served from 1994 to 2004. From 1987 to 1993, Dr. Peck was Director, Center for Drug Evaluation & Research (CDER), US Food & Drug Administration (FDA) and in 1999, Commissioner Henney presented Dr. Peck with the FDA Distinguished Alumnus Award. Swedens University of Uppsala conferred an honorary doctorate degree (Doctor Honoris Causa) in January 2002 to Dr. Peck in recognition of "outstanding contributions to the science of drug development. Dr. Peck was appointed as Boerhaave Professor of Clinical Drug Research at Leiden University (The Netherlands) in 1993. From 1980 to 1987, Dr. Peck served as Director of the Division of Clinical Pharmacology and, Professor, Departments of Medicine and Pharmacology, Uniformed Services University, Bethesda, Maryland. He was promoted to Assistant Surgeon General in the Public Health Service in October 1990. He received a BA in mathematics and chemistry from the University of Kansas in 1963 and an MD in 1968. Dr. Peck is an author of more than 150 original research papers, chapters and books. He serves on several scientific advisory boards to industry and government institutions, and is a member of several boards of directors.

About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include two former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of approximately 40 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/07/prweb12016944.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.